Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Recruiting Phase 2 Interventional

ASPEN-09-03: A Study of Evorpacept in Combination With Trastuzumab and Chemotherapy in Metastatic HER2-Positive Breast Cancer

ClinicalTrials.gov ID: NCT07007559

Public ClinicalTrials.gov record NCT07007559. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced Sep 6, 2026, 8:32 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

Protocol ASPEN-09-03: A Single-arm Phase 2 Multicenter Study of Evorpacept in Combination With Trastuzumab and Chemotherapy in Participants With Metastatic HER2-Positive Breast Cancer, a Substudy Under Master Protocol ASPEN-09: A Phase 1b/2, Multicenter, Multi Arm Study of Evorpacept in Combination With Anti-cancer Therapies in Advanced / Metastatic Malignancies

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

The Substudy Protocol ASPEN-09-03 is a Phase 2, single-arm, multicenter study evaluating the efficacy, safety, and tolerability of evorpacept in combination with trastuzumab and chemotherapy in participants with HER2-positive metastatic breast cancer who have previously received trastuzumab-deruxtecan. This substudy is actively recruiting. ASPEN-09-03 is a substudy under Master Protocol ASPEN-09, and additional substudies are as follows: * Metastatic colorectal cancer (CRC) - dose escalation phase to evaluate evorpacept in combination with other drugs. This substudy is not open. * Recurrent/metastatic head and neck cancer (HNSCC) - dose escalation phase to evaluate evorpacept in combination with other drugs. This substudy is not open.

Study identification

NCT ID
NCT07007559
Recruitment status
Recruiting
Study type
Interventional
Phase
Phase 2
Lead sponsor
ALX Oncology Inc.
Industry
Enrollment
120 participants

Conditions and interventions

Eligibility (public fields only)

Age range
18 Years and older
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Dec 9, 2025
Primary completion
Nov 30, 2027
Completion
Nov 30, 2028
Last update posted
Aug 13, 2026

2025 – 2028

United States locations

U.S. sites
23
U.S. states
17
U.S. cities
22
Facility City State ZIP Site status
The University of Arizona Cancer Center - North Campus Tucson Arizona 85719 Recruiting
City of Hope Duarte California 91010 Recruiting
UC San Diego Moores Cancer Center La Jolla California 92037 Recruiting
UC Irvine Health - Chao Family Comprehensive Cancer Center Orange California 928686 Recruiting
Saint Joseph Hospital - Cancer Centers of Colorado Denver Colorado 80218 Recruiting
Lutheran Hospital - Cancer Centers of Colorado Golden Colorado 80401 Recruiting
Saint Mary's Regional Hospital - Cancer Centers of Colorado Grand Junction Colorado 81501 Recruiting
The George Washington Medical facility Associates Washington D.C. District of Columbia 20037 Recruiting
Sylvester Comprehensive Cancer Center Miami Florida 33136 Recruiting
City of Hope Chicago Zion Illinois 60099 Recruiting
University of Michigan Rogel Cancer Center Ann Arbor Michigan 48109 Recruiting
HealthPartners Frauenshuh Cancer Center Saint Louis Park Minnesota 55426 Recruiting
Washington University School of Medicine- Siteman Cancer Center St Louis Missouri 63108 Recruiting
St. Vincent Regional Hospital - Cancer Centers of Montana Billings Montana 59102 Recruiting
Oncology Hematology West, Pc Dba Nebraska Cancer Specialists Omaha Nebraska 68130 Recruiting
Memorial Sloan Kettering Cancer Center New York New York 10022 Recruiting
Gabrail Cancer Center Canton Ohio 44718 Recruiting
Oregon Health and Science University Portland Oregon 97239 Recruiting
University of Texas Southwestern Medical Center Dallas Texas 75390 Recruiting
Houston Methodist Cancer Center Houston Texas 77030 Recruiting
The University of Texas M.D. Anderson Cancer Center Houston Texas 77030 Recruiting
Virginia Cancer Specialists Fairfax Virginia 22031 Recruiting
Fred Hutchinson Cancer Center Seattle Washington 98109 Recruiting

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 31 non-U.S. sites.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT07007559, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Aug 13, 2026 · Synced Sep 6, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT07007559 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →